PARP inhibition - opportunities in pancreatic cancer

Shubham Pant^{1

2}, Anirban Maitra^{3

4}, Timothy A Yap^{5

6

7}

Affiliations

¹ Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.
⁶ Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.
⁷ The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.

Comment

Shubham Pant et al. Nat Rev Clin Oncol. 2019 Oct.

. 2019 Oct;16(10):595-596.

doi: 10.1038/s41571-019-0257-6.

Shubham Pant^{1

2}, Anirban Maitra^{3

4}, Timothy A Yap^{5

6

7}

¹ Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.
⁶ Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.
⁷ The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.

No abstract available

Comment on

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Golan T, et al. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157963 Free PMC article. Clinical Trial.